Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 11:48:101061.
doi: 10.1016/j.bbih.2025.101061. eCollection 2025 Oct.

Exploring GPR120/FFAR4 pharmacology: Unveiling novel therapeutic avenues through molecular signaling pathways for Alzheimer's disease intervention

Priyadharshini Gogu  1 , Jayhind Bharti  1 , Jagat Pal Yadav  2 , Maria Grishina  3 , Amita Verma  2 , Vikas Kumar  2 , Ankit Kumar Singh  2   4 , Akash Verma  5 , Pradeep Kumar  4 , Habibullah Khalilullah  6 , Mariusz Jaremko  7 , Abdul-Hamid Emwas  8 , Ashish R Dwivedi  1 , Prateek Pathak  1
Affiliations
Review

Exploring GPR120/FFAR4 pharmacology: Unveiling novel therapeutic avenues through molecular signaling pathways for Alzheimer's disease intervention

Priyadharshini Gogu et al. Brain Behav Immun Health. .

Abstract

G-protein-coupled receptors (GPCRs) are a major class of membrane proteins involved in numerous physiological and pathological processes. Among them, free fatty acid receptor 4 (FFAR4/GPR120), activated by long-chain free fatty acids, has shown anti-inflammatory effects and is expressed in the brain-implicating its role in neurodegenerative diseases like Alzheimer's disease (AD). AD is characterized by brain atrophy, cognitive decline, and neuroinflammation, involving complex signaling networks. This review explores the pharmacological relevance of GPR120/FFAR4 in AD, focusing on its involvement in neuroinflammatory, amyloidogenic, and intracellular signaling cascades. Targeting GPR120 may help modulate chronic inflammation and amyloid-β accumulation. Additionally, activation of nuclear receptors and regulation of pathways such as MAPK, NLRP3, PPARs, and cAMP have shown promise in mitigating AD pathology. Despite the complexity of brain signaling, GPR120 emerges as a compelling multitarget therapeutic receptor. These insights provide a foundation for developing novel anti-inflammatory strategies in AD treatment.

Keywords: GPCR; MAPK; NLRP3; Neuroinflammation; Neuroprotection; PPARs; Therapeutic targets.

PubMed Disclaimer

Conflict of interest statement

Authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Molecular ligands of GPR120.
Fig. 2
Fig. 2
GPR120 distribution and physiological functions.
Fig. 3
Fig. 3
GPR120 pharmacological role.
Fig. 4
Fig. 4
NLRP3 signaling pathway: Activation of the NLRP3 inflammasome signaling pathway stimulates the production of several inflammasome components such as protein NLRP3, pro-IL-1β, and pro-IL-18. NLRP3 inflammasome oligomerization leads to caspase-1 activation and IL-1β and IL-18 release, subsequently resulting in neurodegenerative disease.
Fig. 5
Fig. 5
Proteolytic breakdown of amyloid precursor protein (APP) and Aβ biogenesis.
Fig. 6
Fig. 6
Amyloidogenic and non-amyloidogenic processing pathway of APP.
Fig. 7
Fig. 7
Structures of omega-3 fatty acids.
Fig. 8
Fig. 8
The ERK- mediate signaling pathway.
Fig. 9
Fig. 9
cAMP signaling pathway and cAMP in vascular theory A) ACs promote intracellular cAMP accumulation, which activates protein kinase A (PKA), leading to phosphorylation of cAMP-response element binding protein (CREB), which translocates to the nucleus anti-inflammatory cytokines and production of pro-resolving mediators. B) cAMP exerts a protective effect on the integrity of the endothelium in the BBB, and any inflammatory mediators result in the development of neurodegenerative diseases.
Fig. 10
Fig. 10
Schematic of fatty acids receptor system.
Fig. 11
Fig. 11
Crystal structure (PDB-ID: 3DZY) of the PPARs.
See this image and copyright information in PMC

References

    1. Aarti S., Priyanka B. Review on therapeutic effects mediated by omega-3 fatty acids in alzheimer's disease. Asian J. Pharmaceut. Clin. Res. 2018;11(2):54. doi: 10.22159/ajpcr.2018.v11i2.22435. - DOI
    1. Adler B.L., Yarchoan M., Hwang H.M., Louneva N., Blair J.A., Palm R., Smith M.A., Lee H., Arnold S.E., Casadesus G. Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition. Neurobiol. Aging. 2014;35(4):793–801. doi: 10.1016/j.neurobiolaging.2013.10.076. - DOI - PubMed
    1. Ahmed M.R., Jayakumar M., Ahmed M.S., Zamaleeva A.I., Tao J., Li E.H., Job J.K., Pittenger C., Ohtsu H., Rajadas J. Pharmacological antagonism of histamine H2R ameliorated L-DOPA–induced dyskinesia via normalization of GRK3 and by suppressing FosB and ERK in PD. Neurobiol. Aging. 2019;81:177–189. doi: 10.1016/j.neurobiolaging.2019.06.004. - DOI - PubMed
    1. Albert-Gascó H., Ros-Bernal F., Castillo-Gómez E., Olucha-Bordonau F.E. MAP/ERK signaling in developing cognitive and emotional function and its effect on pathological and neurodegenerative processes. Int. J. Mol. Sci. 2020;21(12):4471. doi: 10.3390/ijms21124471. - DOI - PMC - PubMed
    1. Almeida-da-Silva C.L.C., Savio L.E.B., Coutinho-Silva R., Ojcius D.M. The role of NOD-like receptors in innate immunity. Front. Immunol. 2023;14 doi: 10.3389/fimmu.2023.1122586. - DOI - PMC - PubMed

LinkOut - more resources